Top

Published in:

01-03-2017 | Original Article

Voriconazole-induced periostitis: a new rheumatic disorder

Author: Marwan H. Adwan

Published in: Clinical Rheumatology | Issue 3/2017

Abstract

Over the past few years, several reports of periostitis affecting patients treated with voriconazole appeared in the literature. As rheumatologists are likely to be called to see such patients, a review of the reported cases was undertaken. A systematic search of Pubmed and Google scholar for case reports, case series and observational studies was undertaken. Twenty-six articles including 23 case reports/case series (total 40 patients), a prospective study and two retrospective studies of 58 cases were included. Age ranged from 3 months to 77 years. Eleven cases (27.5 %) were male and 29 cases (72.5 %) were female. The duration of treatment varied from 6 weeks to 8 years (mean 53.6, SD 77.4 weeks). Most cases presented with diffuse skeletal pain affecting various sites in association with elevated alkaline phosphatase. Periostitis is increasingly reported and should be considered in patients taking voriconazole who present with bone pain and/or alkaline phosphatase elevation.

Saravolatz LD, Johnson LB, Kauffman CA (2003) Voriconazole: a new triazole antifungal agent. Clin Infect Dis 36(5):630–637CrossRef

Barry AL, Brown SD (1996) In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Antimicrob Agents Chemother 40(8):1948–1949PubMedPubMedCentral

Dickinson RP et al (1996) Novel antifungal 2-aryl-1-(1H-1, 2, 4-triazol-1-yl) butan-2-ol derivatives with high activity against Aspergillus fumigatus. Bioorg Med Chem Lett 6(16):2031–2036CrossRef

Radford SA, Johnson EM, Warnock DW (1997) In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob Agents Chemother 41(4):841–843PubMedPubMedCentral

Martin M, Yates J, Hitchcock C (1997) Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob Agents Chemother 41(1):13–16PubMedPubMedCentral

Wingard JR et al (2010) Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 116(24):5111–5118CrossRefPubMedPubMedCentral

Mehrad B et al (2001) Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature. Chest J 119(1):169–175CrossRef

Patterson TF et al (2000) Invasive aspergillosis disease spectrum, treatment practices, and outcomes. Medicine 79(4):250–260CrossRefPubMed

Walsh TJ et al (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46(3):327–360CrossRefPubMed

10.

Wang TF et al (2009) Periostitis secondary to prolonged voriconazole therapy in lung transplant recipients. Am J Transplant 9(12):2845–2850CrossRefPubMed

11.

Ayub A, Kenney CV, McKiernan FE (2011) Multifocal nodular periostitis associated with prolonged voriconazole therapy in a lung transplant recipient. J Clin Rheumatol 17(2):73–75CrossRefPubMed

12.

Baird JH et al (2015) Voriconazole‐induced periostitis after allogeneic stem cell transplantation. Am J Hematol 90(6):574–575CrossRefPubMed

13.

Becce F et al (2012) Clinical images: voriconazole-induced periostitis deformans. Arthritis Rheum 64(10):3490CrossRefPubMed

14.

Davis DL (2015) Voriconazole-related periostitis presenting on magnetic resonance imaging. Clin Cases Miner Bone Metab 12(1):78–81PubMedPubMedCentral

15.

Gladue HS, Fox DA (2013) Voriconazole-induced periostitis causing arthralgias mimicking a flare of granulomatosis with polyangiitis. J Clin Rheumatol 19(8):444–445CrossRefPubMed

16.

Glushko T, Colmegna I (2015) Voriconazole-induced periostitis. CMAJ 187(14):1075CrossRefPubMedPubMedCentral

17.

Hirota K, et al (2014) Voriconazole-induced periostitis in a patient with overlap syndromes. BMJ Case Rep 2014. doi: 10.1136/bcr-2013-203485.

18.

Lustenberger DP, Granata JD, Scharschmidt TJ (2011) Periostitis secondary to prolonged voriconazole therapy in a lung transplant recipient. Orthopedics 34(11):e793–e796PubMed

19.

Paudyal S et al (2015) Fluffy periostitis induced by voriconazole. Arthritis Rheumatol 67:3297CrossRefPubMed

20.

Rad B et al (2015) Fluorosis and periostitis deformans as complications of prolonged voriconazole treatment. Ann Clin Biochem 52(Pt 5):611–614CrossRefPubMed

21.

Raghavan M, Hayes A (2014) Voriconazole-associated soft tissue ossification: an undescribed cause of glenohumeral joint capsulitis. Skeletal Radiol 43(9):1301–1305CrossRefPubMed

22.

Rossier C et al (2012) Voriconazole-induced periostitis. Eur J Nucl Med Mol Imaging 39(2):375–376CrossRefPubMed

23.

Skaug M, Spak C, Oza U (2014) Painful periostitis in the setting of chronic voriconazole therapy. Proc (Bayl Univ Med Cent) 27(4):350–352

24.

Tailor TD, Richardson ML (2015) Case 215: voriconazole-induced periostitis. Radiology 274(3):930–935CrossRefPubMed

25.

Tarlock K et al (2015) Elevated fluoride levels and periostitis in pediatric hematopoietic stem cell transplant recipients receiving long-term voriconazole. Pediatr Blood Cancer 62(5):918–920CrossRefPubMed

26.

Tedja R et al (2013) Multifocal periostitis as a complication of chronic use of voriconazole in a lung transplant recipient. Transpl Infect Dis 15(4):424–429CrossRefPubMed

27.

Wise SM, Wilson MA (2011) A case of periostitis secondary to voriconazole therapy in a heart transplant recipient. Clin Nucl Med 36(3):242–244CrossRefPubMed

28.

Brown A et al (2014) Voriconazole induced periostitis: “rheumatoid arthritis” in a lung transplant patient. Am J Respir Crit Care Med 189:A1588CrossRef

29.

Pampaloni MH (2012) Voriconazole-associated periostitis in a heart transplant patient. J Clin Case Rep 2:166. doi:10.4172/2165-7920.1000166

30.

Bucknor MD, Gross AJ, Link TM (2013) Voriconazole-induced periostitis in two post-transplant patients. J Radiol Case Rep 7(8):10–17PubMedPubMedCentral

31.

Chen L, Mulligan ME (2011) Medication-induced periostitis in lung transplant patients: periostitis deformans revisited. Skeletal Radiol 40(2):143–148CrossRefPubMed

32.

Gerber B et al (2012) Reversible skeletal disease and high fluoride serum levels in hematologic patients receiving voriconazole. Blood 120(12):2390–2394CrossRefPubMed

33.

Rheinboldt M, Delproposto Z, Agarwal R (2015) Voriconazole-induced periostitis post transplant: an illustrative review of thoracic computed tomography imaging manifestations. Transpl Infect Dis 17:859CrossRefPubMed

34.

Wermers RA et al (2011) Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy. Clin Infect Dis 52(5):604–611CrossRefPubMed

35.

Moon WJ et al (2014) Plasma fluoride level as a predictor of voriconazole-induced periostitis in patients with skeletal pain. Clin Infect Dis 59(9):1237–1245CrossRefPubMedPubMedCentral

36.

Skiles JL et al (2011) Fluorosis because of prolonged voriconazole therapy in a teenager with acute myelogenous leukemia. J Clin Oncol 29(32):e779–e782CrossRefPubMed

37.

Ally R et al (2001) A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 33(9):1447–1454CrossRefPubMed

38.

Walsh TJ et al (2002) Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346(4):225–234CrossRefPubMed

39.

Soriano M, Manchon F (1966) Radiological aspects of a new type of bone fluorosis, periostitis deformans 1. Radiology 87(6):1089–1094CrossRefPubMed

40.

Thompson GR et al (2012) Fluoride excess in coccidioidomycosis patients receiving long-term antifungal therapy: an assessment of currently available triazoles. Antimicrob Agents Chemother 56(1):563–564CrossRefPubMedPubMedCentral

41.

Pan L et al (2014) Fluoride promotes osteoblastic differentiation through canonical Wnt/β-catenin signaling pathway. Toxicol Lett 225(1):34–42CrossRefPubMed

42.

Kramer I et al (2010) Osteocyte Wnt/β-catenin signaling is required for normal bone homeostasis. Mol Cell Biol 30(12):3071–3085CrossRefPubMedPubMedCentral

43.

Gaur T et al (2005) Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem 280(39):33132–33140CrossRefPubMed

44.

Krishnan V, Bryant HU, MacDougald OA (2006) Regulation of bone mass by Wnt signaling. J Clin Invest 116(5):1202–1209CrossRefPubMedPubMedCentral

45.

Allen KC et al (2015) Voriconazole enhances the osteogenic activity of human osteoblasts in vitro through a fluoride-independent mechanism. Antimicrob Agents Chemother 59(12):7205–7213CrossRefPubMedPubMedCentral

46.

Silveira L et al (2000) Vascular endothelial growth factor and hypertrophic osteoarthropathy. Clin Exp Rheumatol 18(1):57–62PubMed

47.

Silveri F et al (1996) Hypertrophic osteoarthropathy: endothelium and platelet function. Clin Rheumatol 15(5):435–439CrossRefPubMed

48.

Ron D (2002) Translational control in the endoplasmic reticulum stress response. J Clin Invest 110(10):1383–1388CrossRefPubMedPubMedCentral

49.

Saito A et al (2011) Endoplasmic reticulum stress response mediated by the PERK-eIF2α-ATF4 pathway is involved in osteoblast differentiation induced by BMP2. J Biol Chem 286(6):4809–4818CrossRefPubMed

50.

Schumacher H Jr (1991) Hypertrophic osteoarthropathy: rheumatologic manifestations. Clin Exp Rheumatol 10:35–40

Title: Voriconazole-induced periostitis: a new rheumatic disorder
Author: Marwan H. Adwan
Publication date: 01-03-2017
Publisher: Springer London
Published in: Clinical Rheumatology / Issue 3/2017
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-016-3341-7

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Voriconazole-induced periostitis: a new rheumatic disorder

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2017

The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis

Curvilinear bodies are associated with adverse effects on muscle function but not with hydroxychloroquine dosing

Comorbidity of gout and rheumatoid arthritis in a large population database

Serum 25-OH vitamin D levels in systemic sclerosis: analysis of 140 patients and review of the literature

The functional variants of endothelial nitric oxide synthase gene associated with rheumatoid arthritis in Turkish adults

Refractory ascites in systemic lupus erythematosus: further biological support of intraperitoneal steroid treatment as a suitable therapeutical option

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page